Skip to main content
OpenTrials
Completed

NCT Number: NCT00058955

Physiological, Behavioral and Subjective Effects of Drugs (GHB)

The purpose of this study is to learn more about the effects of gamma-hydroxybutyric acid (GHB) by comparing its physiological, behavioral and subjective effects with those of several other drugs.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–50 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Johns Hopkins University School of Medicine/Bayview Medical Center

Baltimore, Maryland, 21224, United States

About this study

The purpose of this study is to learn more about the effects of gamma-hydroxybutyric acid by comparing its physiological, behavioral and subjective effects with those of several other drugs.

This trial will be conducted as a double-blind, double-dummy, placebo-controlled, counter-balanced (Latin-square design) crossover study in volunteers with histories of sedative abuse. Volunteers will be recruited through advertising and word-of-mouth.

Volunteers will reside on our residential research unit for the duration of the study and participate in a maximum of 16 experimental sessions. Sessions will be conducted five days a week (Monday through Friday). The primary subjective and behavioral measures will be taken before drug administration and at 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours after drug administration.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • are ages 18-50 years
  • have histories of sedative (e.g., GHB, alcohol, benzodiazepine or barbiturate) abuse
  • are within 20% of their ideal body weight
  • are healthy as determined by screening for medical problems via a personal interview, a medical questionnaire, a physical examination, and routine medical blood and urinalysis laboratory tests
  • are not currently pregnant or breast-feeding, if female
  • have signed and dated an informed consent form prior to beginning the study
  • are willing and able to participate

Exclusion criteria

  • have a history or current serious medical or psychiatric conditions, including (but not limited to): heart condition, lung disease, diabetes, seizure disorders, significant gastrointestinal disturbances, narrow angle glaucoma, ulcers, sleep apnea, schizophrenia, personality disorder, bipolar disorder, paranoia, multiple personality disorder
  • have hypersensitivity/allergy or other contraindications to sedatives or stimulants
  • are physically dependent on alcohol or other drugs, excluding nicotine and caffeine
  • are females who are pregnant or are breast feeding
  • are females who become pregnant during the study as evaluated using periodic pregnancy tests

Treatment and study plan

sodium oxybate, triazolam and pentobarbital

Drug

sodium oxybate, triazolam and pentobarbital

Other names: Xyrem

Primary outcomes

  1. Pharmacokinetics

Sponsors and collaborators

Lead sponsor

Orphan Medical

Industry

Collaborators

  • Johns Hopkins University

Registry information

Important dates

Study start
2003
Study completion
2005
First posted
Apr 16, 2003
Registry last updated
Sep 10, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.